ERICKA BROUSSARD: Open Payments
NPI 1962688077 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,740 in 83 payments from 16 companies in 2025. Trend: 2023 $1,110 · 2024 $1,178 · 2025 $1,740
Food & beverage: $1,733Education: $7
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 14 | $363 |
| ABBVIE INC. | 8 | $201 |
| Sumitomo Pharma America, Inc. | 10 | $178 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $161 |
| Currax Pharmaceuticals LLC | 12 | $142 |
| Astellas Pharma US Inc | 8 | $140 |
| E.R. Squibb & Sons, L.L.C. | 1 | $106 |
| Sage Therapeutics, LLC | 4 | $83 |
| Bausch Health US, LLC | 4 | $75 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $65 |
Products named: Auvelity, CAPLYTA, MYFEMBREE, Veozah, CONTRAVE, COBENFY, VRAYLAR, ZURZUVAE.
Industry payments across LA — which companies pay providers there.
